AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Study for Coronary Artery Disease and Type-2 Diabetes

Shots:

• The P-III THEMIS study involves assessing of Brilinta + Aspirin vs Aspirin as monothx. in 19,000+ patients with CAD and T2D with no prior myocardial infarction or stroke across 42 countries including EU, Asia, Africa, North and South America
• The P-III THEMIS study results demonstrated 10% reduction in risk of CV deaths, heart attacks and stroke, 15% reduction in risk in a prespecified sub-analysis of patients who had undergone percutaneous coronary intervention
• Brilinta is a reversible, direct-acting P2Y12 receptor antagonist, act by inhibiting platelet activation, co-administered with aspirin for the prevention of atherothrombotic events in patients with ACS/prior having MI and a high risk of developing an atherothrombotic event

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Bloomberg Quint